SLRN

Acelyrin, Inc. (SLRN) | Rumor.io

Acelyrin

SLRN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SLRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Feb 21

Acelyrin, Inc. (SLRN) received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 per share, with a right to receive 80% of proceeds from out-license or disposition of its development programs or intellectual property.
The stock price jumped 14% to $2.48 in premarket trading, with shares having fallen 31% year-to-date prior to the announcement.
The proposed acquisition comes after Acelyrin agreed to merge with Alumis in an all-stock deal expected to close in the second quarter, with the Concentra offer including a contingent value right.

Generated by AI

Sentiment

Of the messages about SLRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	20% -51.59
Bearish	—	—	—	80% +51.59

Bullish· Sep 12

Acelyrin, Inc. has a strong cash position to continue operations and development of Izokibep, with potential changes to the drug and plans to continue development despite recent trial results.
The company's adjusted projections are still at or above $30, indicating potential long-term growth.
The stock is expected to rebound and potentially reach $14.65, with a strong short-term and long-term trend, driven by recent promising news and potential future trials.

Bearish· Sep 12

$SLRN's lead asset failed to meet statistical significance in a Phase 2b/3 trial for treating chronic inflammatory skin disease, resulting in a $1.7 billion market capitalization loss.
Acelyrin's IPO bubble has deflated after the failure of its lead asset, with a 57% pre-market price drop and significant losses for investors, including a 60% decline in market capitalization.
The company's treatment for moderate-to-severe Hidradenitis Suppurativa (HS) failed to meet statistical significance, leading to a 56.6% price drop and a significant decline in investor confidence.

Generated by AI

Topics

Of the messages about SLRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	50%
Announcements	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	100%	100%	100%	50%

May 5

Acelyrin, Inc. (SLRN) raised $540M in its largest biotech IPO since 2021, with the company trading on Nasdaq under the ticker "SLRN".
The IPO was upsized to 30.0mm shares, priced at $18.00 per share, and opened at $23.00 for a gain of 27.8% at first trade.
Acelyrin, a biopharma company focused on providing life-changing new treatment options, aims to accelerate the identification, acquisition, development, and commercialization of clinically meaningful medicines.

Generated by AI

Community

Of the messages about SLRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	9.09%
Newcomers	100%	100%	100%	90.91%

Sep 12

Acelyrin's lead asset izokibep failed to meet the primary endpoint in a Phase 2b/3 trial for treating moderate to severe hidradenitis suppurativa.
The trial's failure resulted in a significant market capitalization drop of over $1.7 billion, with the company's stock price declining by 60% due to the disappointing results.
The failure of izokibep in the trial is seen as a significant setback for Acelyrin, Inc., which had raised $540 million in its IPO in May 2023.

Generated by AI

Also Discussed

Investors talking about SLRN also mention

#	Name	Attention
1	MoonLake Immunotherapeutics Class A Ordinary SharesMLTX	0.01%+0
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
4	MRSN - Mersana Therapeutics, Inc.	——
5	IGMS - IGM Biosciences, Inc.	——
6	ETNB - 89bio, Inc.	——
7	VTYX - Ventyx Biosciences, Inc.	——
8	TERN - Terns Pharmaceuticals, Inc.	——
9	APLS - Apellis Pharmaceuticals, Inc.	——
10	Sagimet Biosciences Inc. Series A Common StockSGMT	0%0

Acelyrin, Inc.

Location

Social

What share of all stock conversation is about SLRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Feb 21

Acelyrin, Inc. (SLRN) received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 per share, with a right to receive 80% of proceeds from out-license or disposition of its development programs or intellectual property.
The stock price jumped 14% to $2.48 in premarket trading, with shares having fallen 31% year-to-date prior to the announcement.
The proposed acquisition comes after Acelyrin agreed to merge with Alumis in an all-stock deal expected to close in the second quarter, with the Concentra offer including a contingent value right.

Generated by AI

Sentiment

Of the messages about SLRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	20% -51.59
Bearish	—	—	—	80% +51.59

Bullish· Sep 12

Acelyrin, Inc. has a strong cash position to continue operations and development of Izokibep, with potential changes to the drug and plans to continue development despite recent trial results.
The company's adjusted projections are still at or above $30, indicating potential long-term growth.
The stock is expected to rebound and potentially reach $14.65, with a strong short-term and long-term trend, driven by recent promising news and potential future trials.

Bearish· Sep 12

$SLRN's lead asset failed to meet statistical significance in a Phase 2b/3 trial for treating chronic inflammatory skin disease, resulting in a $1.7 billion market capitalization loss.
Acelyrin's IPO bubble has deflated after the failure of its lead asset, with a 57% pre-market price drop and significant losses for investors, including a 60% decline in market capitalization.
The company's treatment for moderate-to-severe Hidradenitis Suppurativa (HS) failed to meet statistical significance, leading to a 56.6% price drop and a significant decline in investor confidence.

Generated by AI

Topics

Of the messages about SLRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	50%
Announcements	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	100%	100%	100%	50%

May 5

Acelyrin, Inc. (SLRN) raised $540M in its largest biotech IPO since 2021, with the company trading on Nasdaq under the ticker "SLRN".
The IPO was upsized to 30.0mm shares, priced at $18.00 per share, and opened at $23.00 for a gain of 27.8% at first trade.
Acelyrin, a biopharma company focused on providing life-changing new treatment options, aims to accelerate the identification, acquisition, development, and commercialization of clinically meaningful medicines.

Generated by AI

Community

Of the messages about SLRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	9.09%
Newcomers	100%	100%	100%	90.91%

Sep 12

Acelyrin's lead asset izokibep failed to meet the primary endpoint in a Phase 2b/3 trial for treating moderate to severe hidradenitis suppurativa.
The trial's failure resulted in a significant market capitalization drop of over $1.7 billion, with the company's stock price declining by 60% due to the disappointing results.
The failure of izokibep in the trial is seen as a significant setback for Acelyrin, Inc., which had raised $540 million in its IPO in May 2023.

Generated by AI

Acelyrin

Social

Feb 21

Sentiment

Bullish· Sep 12

Bearish· Sep 12

Topics

May 5

Community

Sep 12

Also Discussed

Acelyrin, Inc.

Company Information

Location

Also Discussed

Social

Feb 21

Sentiment

Bullish· Sep 12

Bearish· Sep 12

Topics

May 5

Community

Sep 12